harrie
06-08-2008, 09:49 PM
Node Negative Early Stage Breast Cancer Patients Benefit From Taxotere®-Based Chemotherapy (http://www.medicalnewstoday.com/articles/108878.php) [Medical News Today (http://www.medicalnewstoday.com/)]
Sanofi-aventis and GEICAM (Grupo Espanol de Investigacion en Cancer de Mama) announced that for women with high-risk node-negative early stage breast cancer adjuvant treatment (post surgery) with Taxotere® (docetaxel) Injection Concentrate as part of the TAC regimen (Taxotere®, doxorubicin, cyclophosphamide) was associated with a significant improvement in Disease Free Survival (DFS) compared to a standard FAC regimen (5-Fluorouracil, doxorubicin, cyclophosphamide) in the GEICAM 9805/Target-0 study.
The results will be presented at the 2008 annual meeting of the American Society of Clinical Oncology, ASCO, in Chicago (Monday June 2, 2008, 2-6 pm, poster number 1D, abstract 542).
In Europe and North America, most breast cancer patients are diagnosed at an early stage, before the tumor has spread to the lymph nodes. However, few clinical trials in the past were dedicated exclusively to this population of patients. GEICAM 9805/Target-0 is the first taxane-based study to exclusively enroll women with node-negative early stage breast cancer considered to be at high risk for recurrence. High risk patients were defined as having at least one of the following St Gallen 1998 criteria: patient's age <35 years, tumor histological grade II/III, tumor size >2 cm, or hormone-receptor (estrogen and/or progesterone receptor) negative tumor.
[NOTE: For the full article, please follow the supplied link.]
ASCO 2008: ABSTRACT #542: Multicenter, randomized phase III study of adjuvant chemotherapy for high-risk, node-negative breast cancer comparing tac with fac: 5-year efficacy analysis of the GEICAM 9805 trial (http://www.abstract.asco.org/AbstView_55_34621.html) [American Society of Clinical Oncology (http://asco.org/)]
Sanofi-aventis and GEICAM (Grupo Espanol de Investigacion en Cancer de Mama) announced that for women with high-risk node-negative early stage breast cancer adjuvant treatment (post surgery) with Taxotere® (docetaxel) Injection Concentrate as part of the TAC regimen (Taxotere®, doxorubicin, cyclophosphamide) was associated with a significant improvement in Disease Free Survival (DFS) compared to a standard FAC regimen (5-Fluorouracil, doxorubicin, cyclophosphamide) in the GEICAM 9805/Target-0 study.
The results will be presented at the 2008 annual meeting of the American Society of Clinical Oncology, ASCO, in Chicago (Monday June 2, 2008, 2-6 pm, poster number 1D, abstract 542).
In Europe and North America, most breast cancer patients are diagnosed at an early stage, before the tumor has spread to the lymph nodes. However, few clinical trials in the past were dedicated exclusively to this population of patients. GEICAM 9805/Target-0 is the first taxane-based study to exclusively enroll women with node-negative early stage breast cancer considered to be at high risk for recurrence. High risk patients were defined as having at least one of the following St Gallen 1998 criteria: patient's age <35 years, tumor histological grade II/III, tumor size >2 cm, or hormone-receptor (estrogen and/or progesterone receptor) negative tumor.
[NOTE: For the full article, please follow the supplied link.]
ASCO 2008: ABSTRACT #542: Multicenter, randomized phase III study of adjuvant chemotherapy for high-risk, node-negative breast cancer comparing tac with fac: 5-year efficacy analysis of the GEICAM 9805 trial (http://www.abstract.asco.org/AbstView_55_34621.html) [American Society of Clinical Oncology (http://asco.org/)]